- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Decoy Therapeutics Highlights Global Access Commitment Agreement in Virtual Investor Segment
Company discusses plans to develop scalable manufacturing platform for peptide-conjugate antivirals with focus on expanding access in low- and middle-income countries.
Published on Feb. 4, 2026
Got story updates? Submit your updates here. ›
Decoy Therapeutics, a preclinical biopharmaceutical company, announced that it participated in a Virtual Investor "What This Means" segment highlighting the company's recently announced Global Access Commitment Agreement (GACA) with the Gates Foundation. The segment provided additional context on Decoy's plans to develop a flexible, globally accessible, and scalable manufacturing platform for peptide-conjugate antivirals, which is a key funded development under the GACA.
Why it matters
Decoy's "design-for-manufacturing" approach aims to enable rapid transition of peptide-conjugate therapeutics from lab to commercial-scale production, and to establish a distributed global manufacturing network capable of responding to emerging viral threats. This aligns with the company's goal of expanding access to its therapies, particularly in low- and middle-income countries.
The details
As part of the segment, Decoy's Chief Business Officer Peter Marschel discussed how the company's platform is designed to enable rapid, cost-efficient manufacturing and scale-up of therapeutics developed through Decoy's proprietary IMP3ACT™ platform. The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor, which is also funded under the Gates Foundation grant.
- The "What This Means" segment was aired on February 4, 2026.
The players
Decoy Therapeutics, Inc.
A preclinical biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics.
Peter Marschel
Chief Business Officer of Decoy Therapeutics.
Gates Foundation
A global health and development organization that has provided funding to Decoy Therapeutics through a Global Access Commitment Agreement.
What they’re saying
“The platform is designed to enable rapid, cost-efficient manufacturing and scale-up of therapeutics developed through Decoy's proprietary IMP3ACT™ platform, with a focus on expanding access in low- and middle-income countries.”
— Peter Marschel, Chief Business Officer (Virtual Investor "What This Means" segment)
What’s next
Decoy plans to validate its globally accessible and scalable manufacturing platform using its intranasal pan-coronavirus fusion inhibitor, which is funded under the same Gates Foundation grant.
The takeaway
Decoy Therapeutics' efforts to develop a flexible and scalable manufacturing platform for peptide-conjugate antivirals, with a focus on expanding access in low- and middle-income countries, demonstrate the company's commitment to making its therapies widely available and responsive to emerging global health threats.
